Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.68 |
| ▸ | CTSK | P43235 | 5/20 | 0.68 |
| ▸ | CTSL | P07711 | 4/20 | 0.68 |
| ▸ | CTSB | P07858 | 3/20 | 0.68 |
| ▸ | CAPN1 | P07384 | 6/20 | 0.67 |
| ▸ | CAPN9 | O14815 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CTSG | P08311 | 1/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18941377 | 1.00 | CTSS (0.68) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL18966404 | 0.90 | CTSS (0.55) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL1237401 | 0.89 | CTSS (0.62) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL12653865 | 0.89 | CTSS (0.62) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL12653615 | 0.89 | CTSS (0.62) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL17449484 | 0.88 | CTSS (0.68) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL28969921 | 0.88 | CTSS (0.68) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL14104498 | 0.87 | CTSK (0.67) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL9889092 | 0.87 | CTSK (0.67) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL8693200 | 0.87 | CTSS (0.67) | CTSSCTSKCTSLCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022418-B2 | Compositions and methods for treating beta-amyloid related diseases | AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-2921486-B1 | Compositions and methods for treating beta-amyloid related diseases | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20170166543-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166543-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2017-06-15 | — | — | US | disclosed |
| WO-2015117094-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER | AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| EP-0753003-B1 | AZIRIDINE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-06-16 | — | — | EP | disclosed |
| US-5668128-A | INHIBITORS OF THIOL PROTEASE, PROPHYLAXIS AND TREATMENT OF BONE DISEASES, OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-16 | — | — | US | disclosed |
| EP-0753003-A1 | AZIRIDINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-01-15 | — | — | EP | disclosed |
| WO-1995028416-A1 | AZIRIDINE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-26 | — | — | WO | disclosed |
| US-5214056-A | Thiol protease inhibitors | JAPAN TOBACCO INC. (JP) | 1993-05-25 | — | — | US | disclosed |
| EP-0460239-A1 | 1,3,2-DIOXATHIOLANE OXIDE DERIVATIVE | Japan Tobacco Inc. (JP) | 1991-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022418-B2 | Compositions and methods for treating beta-amyloid related diseases | APP, BACE1, PTMS | CTSS 111/4885CTSK 979/4885CTSL 82/4885 |
| US-20170166543-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER | PTMS, LTA, LPXN | CTSS 2247/4885CTSK 4083/4885CTSL 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.